Navigation Links
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
Date:6/10/2008

Phase 3 data highlight sustained efficacy and benefits of early treatment

with liraglutide versus glimepiride

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-daily liraglutide when taken alone produced statistically significant improvement in blood sugar (glucose) control in patients with type 2 diabetes, as compared to glimepiride, a widely used oral anti-diabetic drug (OAD).

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/novonordisk/33424/

In addition, liraglutide demonstrated the following benefits compared to glimepiride:

-- Statistically significant reduction in body weight

-- Statistically significant reduction in risk of hypoglycemia

-- Statistically significant reduction in systolic blood pressure

In this 12-month study, 62% of patients treated with liraglutide who had not been previously treated with diabetes medications achieved an average reduction in blood sugar that brought them below the ADA target for HbA1c of 7%.

"This study showed that when used as initial drug treatment for type 2 diabetes, once-daily liraglutide not only statistically significantly reduced blood glucose, weight, and systolic blood pressure, but sustained blood glucose reductions for the duration of the study in patients who had never taken diabetes medications before," said study investigator Robert E. Ratner, MD, Vice President for Scientific Affairs at the MedStar Research Institute in Washington, DC. "The sustained reduction in blood glucose suggests that liraglutide may be beneficial when used earlier in the course of diabetes."

About the Study

The data presented today are from the LEAD(TM) 3 study, one of the five studies which make up the Phase 3 program for liraglutide.

The double-blinded, double-dummy, randomized, parallel group, actively-controlled, multicenter, multinational 52-week trial compared the efficacy and safety of two doses of liraglutide (1.2 and 1.8 mg once daily) to glimepiride (8 mg once daily) in patients with type 2 diabetes treated with diet/exercise or not more than half the maximum dose of one OAD for greater than or equal to two months. Patients treated with diet and exercise had HbA1c between 7.0% and 11.0%. Patients previously treated with oral monotherapy had an HbA1c between 7.0% and 10.0%.

The data showed that at both doses tested, liraglutide provided substantial improvement in glucose control from baseline and statistically significantly better glucose control than glimepiride. Patients previously treated with diet and exercise had greater decreases in HbA1c, as compared to subjects switched from an OAD to liraglutide.

In addition, there was significant weight loss, as compared to weight gain with glimepiride, and significantly greater reduction in systolic blood pressure with both liraglutide groups compared to glimepiride.

Results of a 52-week trial of liraglutide monotherapy in patients with inadequate glucose control from previous diet and exercise or treatment with one OAD:

Monotherapy

Liraglutide Liraglutide Glimepiride

1.8 mg 1.2 mg

N 246 251 248

HbA1c (%) (Mean)

Baseline 8.2 8.2 8.2

Change from baseline -1.14 -0.84 -0.51

Previous diet/exercise-

treated patients -1.60 -1.19 -0.88

Previous OAD-treated

patients -0.71 -0.47 -0.17

Patients (%)

achieving HbA1C <7%

All patients 50.9 42.8 27.8

Previous diet-treated

patients 62.0 58.3 30.8

Body Weight (kg) (Mean)

Baseline 92.6 92.1 93.3

Change from baseline -2.45 -2.05 1.12

Safety and Tolerability of Liraglutide

There were no major hypoglycemic episodes reported during the study. The rate of minor hypoglycemia was statistically significantly lower in both liraglutide dose groups compared with the glimepiride-treated group. The most common adverse events were nausea, diarrhea, and vomiting, and most were short-term and mild or moderate in severity.

About Liraglutide

Liraglutide is a once-daily analog of the naturally occurring hormone human Glucagon-Like Peptide-1 (GLP-1). Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration (FDA) in the US as well as a marketing authorization application to the European Medicines Agency (EMEA) in Europe, for the approval of liraglutide for the treatment of patients with type 2 diabetes.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) Program consists of five (four 26-week and one 52-week) randomized, controlled, double-blinded studies, involving more than 4000 patients with type 2 diabetes in 40 countries.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... 2016  Diana Russell suffers from a form of ... inside out.  This disease has put her in a ... and grandchildren to leave her home.  Because of the ... haul the wheelchair.  So if there is a family ... is left to wait for the bus. ...
(Date:5/24/2016)... May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... on advancing renal care, today announced that Jeffrey ... in the following schedule of investor conferences. Where applicable, ... at http://ir.nxstage.com/ .   ... Conference NY, NY           Friday, June 10, 2016 1:30 ...
Breaking Medicine Technology:
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... Whole Health ... jaw clipper that has been available via Amazon.com. This new style of nail ... nails. , The jaw opening is approximately 4mm and the actual handle is 2.5mm ...
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In search of the K. ... theme event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites ... is sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. ... from leading advocates, associations and industry leaders such as Bioness. , As ...
(Date:5/27/2016)... PALMYRA, Wis. (PRWEB) , ... May 27, 2016 ... ... over $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this ... She accepted her award on May 18 at the university’s Student Leadership Awards ...
Breaking Medicine News(10 mins):